ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air^® partnered with Two Onc Docs to bring you insights on the primary results of the phase 3 LAURA trial (NCT03521154), which were presented at the 2024 ASCO Annual Meeting by Suresh S. Ramalingam, MD, FACP, FASCO, of the Winship Cancer Institute of Emory University in Atlanta, Georgia. LAURA evaluated osimertinib following chemoradiation in patients with stage III, unresectable, EGFR-mutated non–small cell lung cancer (NSCLC). Drs Armstrong and Tawagi shared lung cancer staging tips; explained standard treatment strategies for stage I, II, and IIIA NSCLC; highlighted key findings from LAURA; and discussed questions raised by the trial’s design and its findings.